Shalini Shenoy, M.D.  shenoy@wustl.edu

Professor of Pediatrics, Washington University in St. Louis
Patient Oriented Research UnitHematology and Oncology

phone: (314) 454-6018

Clinical Interests

Dr. Shenoy's research interests are focused on stem cell transplants for non-malignant disorders, reduced intensity transplants, and the immunologic mechanisms of graft rejection, graft versus host disease (GVHD), and immune reconstitution following stem cell transplantation (SCT). These efforts are directed at making SCT safer and better tolerated by reducing associated toxicities, especially as it relates to non-malignant disorders such as hemoglobinopathy. She is the Prinicipal Investigator of national trials of unrelated donor transplantation for severe sickle cell disease termed the SCURT Trial (Bone Marrow Transplant Clinical Trials Network 0601, NHLBI) and thalassemia termed the URTH Trial (Thalassemia Clinical Research Network, NHLBI). Other clinical trials for additional non-malignant disorders such as bone marrow failure syndromes using alternative and minimally mismatched donors are also underway.

Education

  • MBBS, Kasturba Medical College1981
  • MD, Kasturba Medical College1985
  • MD, Louisiana State University Medical Center1991
  • MD, Washington University in St. Louis1996

Training

  • Residency in Pediatrics, Kasturba Medical College1982 - 1985
  • Residency in Pediatrics, Louisiana State University Medical Center1989 - 1991
  • Fellowship in Pediatric Hematology Oncology, Washington University in St. Louis1992 - 1996

Licensure and Board Certification

  • MO, MD
  • Pediatric Hematology Oncology

Honors

  • American Society of Histocompatibility and Immunogenetics Scholar Award2001 - 2001
  • Fred Saunders Lecture Award, CBMTG2012 - 2012
  • Teresa J Vietti MD Scholar in Pediatrics, Washington University School of Medicine in St. Louis2014 - Pres

Recent Publications view all (51)


  1. Awareness of cord blood collection and the impact on banking. Pediatr Blood Cancer. 2017. PMID:28111924 
  2. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Children with Sickle Cell Disease and Thalassemia: a Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017. PMID:28065838 
  3. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation (HCT): Defining the Unique Late Effects of Children Undergoing HCT for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant. 2016. PMID:27737772 
  4. Unrelated Donor Bone Marrow Transplantation for Children with Severe Sickle Cell Disease: Results of a Phase II Trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2016. 
  5. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016;22(8):1467-72. PMID:27164064 
  6. Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation". Biol Blood Marrow Transplant. 2016. PMID:27343717 
  7. Unrelated donor stem cell transplantation for transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):122-6. PMCID:PMC4870105  PMID:26999376 
  8. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015. doi:10.1002/ajh.24183  PMID:26348869 
  9. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015;62(7):1270-6. doi:10.1002/pbc.25458  PMID:25755151 
  10. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.03.019  PMID:25840334 
  11. Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. J Pediatr Hematol Oncol. 2015;37(2):e94-e101. doi:10.1097/MPH.0000000000000272  PMCID:PMC4337424  PMID:25333837 
  12. Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders. Curr Opin Pediatr. 2015;27(1):9-17. doi:10.1097/MOP.0000000000000179  PMCID:PMC4403859  PMID:25565572 
  13. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089-94; quiz 3210. doi:10.1182/blood-2013-01-435776  PMID:24511087 
  14. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014;123(10):1615-20. doi:10.1182/blood-2013-10-535716  PMCID:PMC3945869  PMID:24435046 
  15. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion. 2014;54(2):384-8. doi:10.1111/trf.12258  PMID:23692505 
  16. Exposure of early pediatric trainees to blood and marrow transplantation leads to higher recruitment to the field. Biol Blood Marrow Transplant. 2013;19(9):1399-402. doi:10.1016/j.bbmt.2013.06.021  PMID:23838095 
  17. Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant. 2013;19(9):1279-87. doi:10.1016/j.bbmt.2013.07.006  PMID:23883618 
  18. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013;19(8):1238-43. doi:10.1016/j.bbmt.2013.05.021  PMCID:PMC3736557  PMID:23751955 
  19. Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med. 2013;2(5):337-40. doi:10.5966/sctm.2012-0180  PMCID:PMC3667562  PMID:23580541 
  20. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-96. doi:10.1056/NEJMoa1203517  PMID:23075175 
  21. Human polyomaviruses in children undergoing transplantation, United States, 2008-2010. Emerg Infect Dis. 2012;18(10):1676-9. doi:10.3201/eid1810.120359  PMCID:PMC3471627  PMID:23017293 
  22. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18(8):1265-72. doi:10.1016/j.bbmt.2012.01.019  PMCID:PMC3618440  PMID:22343376 
  23. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-95. doi:10.1182/blood-2011-11-393975  PMCID:PMC3383014  PMID:22566601 
  24. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus. Pediatr Blood Cancer. 2012;58(6):988-91. doi:10.1002/pbc.23187  PMID:21618414 
  25. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program. 2011;2011:273-9. doi:10.1182/asheducation-2011.1.273  PMID:22160045 
  26. Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2010;16(9):1212-21. doi:10.1016/j.bbmt.2009.12.536  PMCID:PMC2891395  PMID:20079865 
  27. Severe sickle cell disease--pathophysiology and therapy. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S64-7. doi:10.1016/j.bbmt.2009.10.001  PMCID:PMC2832723  PMID:19819341 
  28. Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2010;54(1):154-7. doi:10.1002/pbc.22283  PMID:19760774 
  29. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplant. 2009;43(4):307-14. doi:10.1038/bmt.2008.327  PMCID:PMC2792985  PMID:19011666 
  30. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008;42(3):159-65. doi:10.1038/bmt.2008.151  PMID:18500373 
  31. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50(4):822-5. doi:10.1002/pbc.21264  PMID:17570702 
  32. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008;41(4):349-53. doi:10.1038/sj.bmt.1705926  PMID:18026148 
  33. Stem cell transplantation in genetically linked regulatory T-cell disorders. Chem Immunol Allergy. 2008;94:211-9. doi:10.1159/000155089  PMID:18802350 
  34. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant. 2008;41(2):141-8. doi:10.1038/sj.bmt.1705961  PMID:18176616 
  35. Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant. 2007;40(9):813-21. doi:10.1038/sj.bmt.1705779  PMID:17704797 
  36. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(10):1201-6. doi:10.1016/j.bbmt.2007.06.012  PMID:17889357 
  37. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood. 2007;109(1):383-5. doi:10.1182/blood-2006-05-025072  PMID:16990602 
  38. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion. 2006;46(1):14-23. doi:10.1111/j.1537-2995.2005.00665.x  PMID:16398726 
  39. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7(2):143-6. doi:10.109701.GIM.0000154299.22120.6A  PMID:15714083 
  40. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345-52. doi:10.1038/sj.bmt.1704795  PMID:15592491 
  41. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19(1):34-8. doi:10.1038/sj.leu.2403566  PMID:15510203 
  42. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant. 2003;9(11):714-21. doi:10.1016/j.bbmt.2003.08.006  PMID:14652855 
  43. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood. 2003;101(5):2067-9. doi:10.1182/blood-2002-07-2110  PMID:12406871 
  44. Antibodies to 70 kD and 90 kD heat shock proteins are associated with graft-versus-host disease in peripheral blood stem cell transplant recipients. Clin Exp Immunol. 2002;127(3):553-9. PMCID:PMC1906313  PMID:11966775 
  45. Defective apoptosis in lymphocytes and the role of IL-2 in autoimmune hematologic cytopenias. Clin Immunol. 2001;99(2):266-75. doi:10.1006/clim.2001.5017  PMID:11318598 
  46. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood. 2000;95(11):3605-12. PMID:10828051 
  47. Allogeneic peripheral blood stem cell transplantation following CD34+ enrichment by density gradient separation. Bone Marrow Transplant. 2000;25(12):1223-8. doi:10.1038/sj.bmt.1702427  PMID:10871725 
  48. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr. 2000;136(5):682-7. doi:10.1067/mpd.2000.105355  PMID:10802504 
  49. Light microscopic, immunophenotypic, and molecular genetic study of autoimmune lymphoproliferative syndrome caused by fas mutation. Pediatr Dev Pathol. 2000;3(1):101-9. PMID:10594139 
  50. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 1999;23(4):335-46. doi:10.1038/sj.bmt.1701581  PMID:10100577 
  51. Unrelated donor stem cell transplantation for transfusion-dependent thalassemia PMCID:PMC4870105  
Wash U School of Medicine
Children's Hospital St. Louis
Children's Discovery Institute
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130